Polycyclic aromatic hydrocarbons (PAHs) are widespread environmental carcinogenic pollutants and they have become an important issue in food contamination. Dietary intake of PAHs has been recognized as a major route of human exposure. However, the mechanisms behind dietary PAH-induced colorectal cancer (CRC) remain unclear. Several studies have shown that polymethoxyflavones (PMFs) are effective in preventing carcinogen-induced CRC or colitis. In this study, we investigated the preventive effect of PMFs on benzo[a]pyrene/dextran sulfate sodium (BaP/DSS)-induced colorectal tumorigenesis in ICR mice. We found that PMFs significantly prevented BaP/DSS-induced colorectal tumor formation. BaP mutagenic metabolite and DNA adducts were found to be reduced in colonic tissue in the PMFs-treated groups through the modulation of BaP metabolism. At the molecular level, the results of RNA-sequencing indicated that PMFs ameliorated BaP/DSS-induced abnormal molecular mechanism change including activated inflammation, downregulated anti-oxidation targets, and induced metastasis genes. The autophagic defect caused by BaP/DSS-induced tumorigenesis was improved by pretreatment with PMFs. We found BaP/ DSS-induced CRC may be a Wnt/b-catenin independent process. Additionally, consumption of PMFs extracts also altered the composition of gut microbiota and made it similar to that in the control group by increasing butyrate-producing probiotics and decreasing CRC-related bacteria. BaP in combination with DSS significantly induced colorectal tumorigenesis through induced DNA adduct formation, abnormal gene expression, and imbalanced gut microbiota composition. PMFs were a powerful preventive agent that suppressed BaP/DSS-induced CRC via modulating multiple pathways as well as ameliorating autophagic defect. These results demonstrated for the first time the chemopreventive efficacy and comprehensive mechanisms of dietary PMFs for preventing BaP/DSS-induced colorectal carcinogenesis.
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and second most commonly diagnosed cancer in females worldwide with an annual incidence of 1.4 million new cases and over 160,000 deaths. 1 Epidemiological studies demonstrated that environmental and lifestyle factors, including dietary habits and components, have been strongly associated with CRC development. 2, 3 According to recent literature by Harrad and Ma, dietary intake has been the major vehicle of human exposure to polycyclic aromatic hydrocarbons (PAHs). 4 They are recognized as having hazardous mutagenic and carcinogenic potential in mammals and present an increasingly serious issue to food safety and food contamination. 4 One of the most significant current discussions in PAHs exposure focuses on an increased risk of CRC through environment, occupation and dietary intake. 5, 6 PAHs can contaminate foods through both natural and anthropogenic sources including cooking, smoke, barbeque and industrial food processing. 7 When PAHs enter the body, their bioactivation is thought to be catalyzed by cytochrome P450s (CYPs), also called phase I enzymes, to form the ultimate mutagenic metabolite such as benzo [a] pyrene (BaP) converted to mutagenetic BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) that can react with DNA to lead BPDE-DNA adduct formation and consequent gene mutation, thus initiating tumorigenesis. 8 Nevertheless, previous study suggested that mice orally administrated BaP found the highest mutation frequency in the colon but it did not induce colorectal tumorigenesis. This limitation may be due to a lack of promotion/progression factors. 2, 9 Several factors act as potential tumorigenesis promoters such as a polluted environment, intangible stress, western diet patterns and individual heredity. [10] [11] [12] Those factors significantly increase the risk of CRC development when followed by the ingestion of PAHscontaminated foods. 13 However, the underlying molecular mechanisms behind dietary PAHs combined with promotion factor-induced CRC remain unclear. Therefore, investigation of dietary PAHs, particularly BaP that is a representative carcinogen species for PAHs, in inducing colorectal tumorigenesis is essential. CRC development, a dynamic and long-term process, involves many complex factors such as DNA mutation, signaling pathway disorder, and colonic microbiota imbalance. 14, 15 During colorectal tumorigenesis, chemicals or free radicals induce DNA damage/mutation that plays an initiation role affecting cell growth regulation, oncogene/ tumor suppressor gene (TSG) expression and cell differentiation. Therefore, the strategy of a chemoprevention approach targeting the initiation stage is desirable in order to block tumor development. This is accomplished through modulation of the type and expression level of xenobiotic metabolizing enzymes (XEMs) to reduce the production of reactive metabolites or increase the ability of antioxidative stress. 16, 17 Following initiation, promotion is a prolonged stage that contain several reversible mechanisms in the process of tumor promotion such as cell cycle dysregulation, uncontrolled cell proliferation, programmed cell death (PCD) disorder and excessive inflammatory response. 15, 18 Therefore, intervention in the promotion stage is a suitable and useful strategy. Additionally, recent evidence demonstrated that gut microbiota is implicated in variety of chronic diseases including diabetes, bowel diseases and CRC. 19, 20 Accumulating reports suggest that the composition of gut microbiota is closely correlated with colorectal tumorigenesis, which includes the initiation and promotion/progression stages. 21 For instance, Baxter et al. found an increase of Parabacteroides and Akkermansia in the feces of humans with a higher rate of colon tumorigenesis. 22 In contrast, an increased amount of Lactobacillus salivarius contributed to reduced colonic inflammatory responses and prevented colorectal carcinogenesis. 23, 24 In this study, we investigate how the BaP in combination with dextran sodium sulfate (DSS), the most common tumorigenic promoter for inducing colitis in the murine model, induced colorectal tumorigenesis and it was prevented by polymethoxyflavones (PMFs), which was isolated from citrus peels and have been shown to exhibit various biological activities including cancer prevention, anti-inflammatory activity and inhibition of metastasis. 15 We found that the oral admin- made it similar to that in the control group by increasing the butyrate-producing probiotics and decreasing CRC-related bacteria. We hope this study will contribute to the explanation of PAHs-induced CRC development and prevention through dietary PMFs.
Material and Methods

Reagents
BaP was purchased from Sigma Chemical Co. DSS (molecular weight of 36,000-50,000 g/mol) was purchased from ICN Biomedicals. PMFs were obtained from Florida Flavors Company (Lakeland, FL, USA) and their composition was determined by high-performance liquid chromatography (HPLC) as shown in Supporting Information, Figure S1 and Table S1 .
Animals and experimental procedure
Male ICR (Institute for Cancer Research) mice at 4-6 weeks of age were purchased from the BioLASCO experimental animal center (Taiwan Co., Taipei, Taiwan), housed in metal wire-bottomed cages and acclimatized under a controlled atmosphere (25 6 18C, 50% relative humidity, 12 hrs light/12 hrs dark cycle). All mice were fed standard AIN-76 diet and top water ad libitum at all times, acclimatized for one week, and then randomly distributed by body weight into control and experimental groups. All protocol used in these animal experiments were approved by Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (project number: B201600115). The animal experimental design for this study is shown in Figure 1a . Experimental animals were randomly allotment into five groups: control, PMFs alone, BaP/DSS, 0.5% PMFs 1 BaP/DSS and 1.0% PMFs 1 BaP/DSS. Mice in BaP/ DSS treatment groups were administered BaP orally (125 mg/kg/day for 5 days), followed by 2% DSS in drinking water (supplied twice, with a two-week interval). The PMFs treatment groups were fed diets containing 0.5% or 1.0% PMFs, respectively, until the end of the study. In mice treated with BaP, we also collected feces for the analysis of BaP metabolites by LC/MSMS. At 8 weeks, all mice were euthanized by CO 2 asphyxiation for examination of molecular and histopathological changes in the colon tissues. Blood samples were collected and isolated in serum for biochemical analysis. The liver, spleen and kidneys were also immediately removed and weighted.
Immunohistochemical analysis (IHC)
Colon tissues were fixed overnight in 10% buffered formalin and embedded in paraffin. Sections of 3 lm thickness were incubated with 0.3% hydrogen peroxide to quench the endogenous peroxidase activity and then were heated in Tris (hydroxymethyl) aminomethane-ethylenediaminetetraacetic acid (Tris-EDTA) buffer (10 mM Tris, 1 mM EDTA, pH 9) in a microwave oven for antigen retrieval. After antigen retrieval, sections were incubated with the primary antibody to microtubule-associated protein 1 light chain 3II (LC3II), lysosomal-associated membrane protein 1 (LAMP1), and proliferating cell nuclear antigen (PCNA) for 1 hr at room temperature. Sections were then incubated with a biotinconjugated horseradish peroxidase secondary antibody (3, 3 0 -diaminobenzidine tetrahydrochloride was used as the substrate) or fluorescent-dye-conjugated secondary antibody.
BPDE-DNA adduct determination by ELISA kit
Genomic DNA was isolated from colonic mucosa as described previously. 25 The extracted genomic DNA was used for determining the concentration of BPDE-DNA adducts through use of a BPDE-DNA adduct kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer's instruction.
Detection of BaP metabolites from feces by UPLC/MSMS
Feces samples of the mice were collected during their initial oral dose of BaP to 6 days. 200 mg of the feces sample and 1 ml acetonitrile were placed in an Eppendorf with sonication for 10 min at room temperature. The supernatant was collected and filtrated with 0.22 lm PTFE membrane. BaP metabolites were determined by the Water UPLC system (Acquity, Waters, Mildford, MA, USA) interfaced to a triple quadrupole mass spectrometer (TQS, Waters Micromass, Manchester, UK) equipped with an electrospray ionization source (ESI). The separation of BaP metabolites was conducted using a Waters ACQUITY UPLC BEH phenyl column (1.7 lm; 2.1 mm 3 150 mm) at 458C. Ultrapure water (A) and acetonitrile (B) containing 0.1% formic acid were used as the mobile phase. The gradient of chromatographic separation was as follows: 0-10 min (75/25, A/B) to (5/95, A/B) and kept for 1 min; followed by an increase to 75% A during 0.5 min and held for 0.5 min to allow for equilibration. Positive ESI ions in a multiple reaction monitoring (MRM) model with collision energy of 35 eV, 35 eV, 50 eV and 45 eV were used to determine BaP (m/z 252 5> 252), BaP-phenols (m/z 268 5> 239), BaP-dihydrodiols (m/z 284 5> 239) and BaP-quinones (m/z 283 5> 226), respectively.
Quantification of mRNA expression by real-time PCR and targeted RNA sequencing
Total RNA from liver and colon tissues were isolated using the Trizol reagent (Invitrogen, Renfrewshire, UK) according to the supplier's protocol and then transcription to complementary DNA using SuperScript III RNA reverse transcriptase (Invitrogen, Renfrewshire, UK). In a real-time PCR analysis, specific primers were designed to clone XMEs as shown in Supporting Information, Table S2 . For RNAsequencing by next generation sequencing (NGS) technology, PCR primers were designed for 114 genes using the primer3 (http://bioinfo.ut.ee/primer3-0.4.0/), and necessary modification was made to span exon-exon junctions. The range of amplicon sizes were among 100-120 bp. The PCR products were purified for NGS library construction by performing end-repairing, adding a-overhang and adaptor ligation. Library preparation was carried out using illumine TruSeq Cancer Therapy and Prevention DNA Sample Prep Kit, and then the reads were pooled equally for sequencing. The total reads of each library ranged from 0.68 to 1 M. After trimming sequences based on quality values (Q30), the reads were mapped to mouse genome GRCm38/mm10 assembly from the UCSC database using Illumina local run manager. Only unimapped reads were used to count expression levels.
Western blot analysis
Scraped colon mucosa tissue was homogenized with gold lysis buffer (50 mM Tris-HCl, 1 mM NaF, 150 mM NaCl, 1 mM EGTA, 1 mM phenylmethanesulfonyl fluoride, 1% NP-40 and 10 lg/mL leupeptin) on ice for 30 min, followed by centrifugation at 12,000g for 30 min at 48C to extract total protein. The protein concentration of supernatant fraction was measured using the Bio-Rad protein assay kit, resolved by SDS-polyacrylamide gel electrophoresis (50 lg protein per lane), and then electroblotted onto polyvinylidene difluoridemembranes. The membranes were blocked with 1% bovine serum albumin solution and immunoblotted overnight at 48C with a primary antibody followed by a secondary antibody conjugated with horseradish peroxidase and visualized using enhanced chemiluminescence (ECL; Amersham Bioscience, Piscataway, NJ, USA). The densities of the bands were quantified with a computer densitometer (AlphaImager TM 2200 System Alpha densitometer, Innotech Corporation, San Leandro, CA, USA).
Taxonomic classification of gut microbiota by next generation sequencing
The genomic DNA of gut bacteria was isolated by the innu-SPEED Stool DNA kit (Analytik Jena AG, Jena, Germany) according to the manufacturer's instructions from intracolonic faeces samples collected from necropsy. The V4 region of bacterial 16S rDNA was amplified using PCR technology with universal primers that were obtained from a previous study. 26 The index-labeled libraries were constructed by used the Illumina DNA library preparation kit (Illumina, San Diego, CA, USA). The library DNA was sequenced by the IlluminaHiSeq2500 platform, and paired-end reads (2 3 150 bp) were generated.
Statistical Analysis
All data are expressed as mean values 6 SD for the indicated number of independently performed experiments. Statistical differences were performed by Student's t tests and one-way ANOVA and Duncan's multiple range tests using SAS statistical software package (version 8.0). Differences with p values <0.05 were considered statistically significant.
Results
Orally administrated PMFs prevent BaP/DSS-induced colorectal tumorigenesis
To examine the preventive effect of PMFs in dietary intake on BaP in combination with DSS-induced colorectal tumorigenesis, we referred to a previous report published by Sonoda et al. to design this experimental model shown in Figure  1a . 27 After the end of the 8 weeks, all mice were sacrificed and the results of body and organ weight were shown in Supporting Information, Figure S2 and Table S3 . We found that mice prefed with PMFs prevented any weight change caused by BaP/DSS. PMFs also abated BaP/DSS-induced liver and kidney toxicity through decreasing AST and ALT and restoring the level of ALP on serum biochemical parameters (Supporting Information, Table S4 ).
The types of polyps including hyperplastic polyp, adenoma and adenocarcinoma were identified by Hematoxylin and eosin (H&E) staining. The microscopic view and tumor counts of colonic tissues showed that PMFs significantly reduced the number of total polyps to 5.8 6 1.8 and 2.6 6 1.1 at 0.5% and 1.0%, respectively, compared with 12.0 6 3.5 in the BaP/DSS-treated group (Fig. 1b and Table 1 ). IHC examination showed that PCNA, a typical cell proliferation biomarker, intensity on both crypt and neoplasia tissue was decreased in mice treated with PMFs compared to the BaP/ DSS group (Fig. 1c) . Together, those results suggested that oral administration of PMFs can prevent BaP/DSS-induced colorectal tumorigenesis.
PMFs decreased BPDE-DNA adduct formation in colon tissue through modulated BaP metabolism
It is well known that the carcinogenic ability of BaP depends on its mutagenic metabolite, BPDE, which reacts with DNA 
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to form covalently DNA adducts and initiates the processes of tumorigenicity. 28 We used IHC with BPDE-DNA adduct antibodies to determine the level and distribution of BPDE-DNA adducts in colonic tissue. The result was shown in Figure 2a . Microscopic views revealed that PMF-treated groups significantly reduced the BPDE-DNA adduct formation at colonic mucosa and submucosa. The BPDE-DNA adduct concentration in colonic tissue was also decreased by PMF treatment in a dose-dependent manner (Fig. 2b) .
To confirm whether PMFs are able to affect BaP metabolism, we analyzed the type of BaP metabolites from feces samples and XEMs expression levels in the liver and colon by UPLC/MSMS and real-time PCR, respectively. We detected 3 main types of BaP metabolites including reactive metabolites such as BaP-quinones and nonreactive metabolites that contain BaP-phenols and BaP-dihydrodiols. 29 The analytic pattern of UPLC/MSMS was shown in Supporting Information, Figure S4 . The concentration of BaP and its metabolites was shown from the average area under curve (AUC). This showed that dietary intake of PMFs contributes to the activation of BaP metabolism through increasing nonreactive metabolites and decreasing reactive metabolites (Fig.  2c) . The XEMs expression level on the liver and colon was also regulated in mice treated with PMFs. PMFs exhibited a suitable inhibition of CYP1As and CYP1Bs on colonic mucosa and significantly induced liver phase II enzymes expression including GSTAs, GSTMs, GSTTs, UGT1As, UGT2s and NOQ1 ( Supporting Information, Fig. S5 ). Those data suggested that PMFs present a downregulation of BaP bioactivation and upregulation of BaP detoxification. Altogether, those results indicated that PMFs exhibit an efficiency in preventing BaP-induced DNA adduct formation via regulation of BaP metabolism and XMEs gene expression.
Comprehensive overview of how gene expression change from PMFs prevents BaP/DSS-induced colorectal carcinogenesis
To examine how the molecular mechanism of BaP/DSSinduced colorectal tumorigenesis is prevented by PMFs, we used RNA-sequencing technology to analyze a variety of CRC development-associated mRNA expressions. As shown in Figure 3a and Supporting Information, Table S5 , when compared with the control group the BaP/DSS treated group markedly upregulated the inflammatory and metastasis gene and downregulated the antioxidation and cell cycle regulators gene. This finding confirms the ability of BaP in combination with DSS to induce colorectal tumor formation.
Meanwhile, the volcano plot was used to identify 111 differentially expressed genes of the 1.0% PMFs prevention groups compared to the BaP/DSS treatment only in colonic tissue (Fig. 3b) . PMFs notably ameliorated BaP/DSS-induced inflammatory responses by inhibiting IL-6, IL-10, TNF-a, COX-2, MCP1 and CXCL-1 and activating antioxidation targets such as HO-1, SODs and NQO1. The fact that PMFs increase TIMPs and decrease MMPs suggests that PMFs possess antimetastasis properties. In particular, protocadherins 17 (PCDH17) exhibited anticancer cell growth and antimetastasis activities by inducing PCD and regulating the cell cycle. 30, 31 In this study, we found that PMFs restored the substantially decreased PCDH17 level in the BaP/DSS-induced tumorigenesis model. The total differentially expressed genes and hierarchical clustering between the control group, the PMFs prevention group, and the BaP/DSS treatment group are exhibited in Figure 3c and Supporting Information, Figure  S6 by Venn diagram and heatmap, respectively.
Inducing defective autophagy may be an important role in BaP/DSS-induced colorectal carcinogenesis independent of the wnt/b-catenin pathway
The Wnt/b-catenin signaling pathway has an important role in modulating carcinogenesis in several tissues, including CRC. 32 During CRC development, most studies suggest that Wnt/b-catenin shows excessively abnormal activation and accumulation of b-catenin in cytoplasm, then subsequently induces aberrant cell proliferation by expressed cell proliferation biomarkers such as cyclin D1 and c-myc. 33, 34 We used western blotting to determine the expression level of bcatenin in colonic tissue and used an individual colonic protein sample extracted from mice treated with azoxymethane for 23 weeks as an independent positive control. Unexpectedly, b-catenin, including total and active form, did not accumulate in cytoplasm in the BaP/DSS-induced CRC model, but the independent positive control did (Fig. 4a) . Therefore, we roughly conjectured that BaP/DSS-induced colorectal tumor formation may be a Wnt/b-catenin independent carcinogenicity process. Nevertheless, results of RNA-sequencing indicated that BaP/DSS treatment significantly increased several non-canonical Wnts expression, including Wnt4, Wnt5a and Wnt11. Previously studies suggested that Ca2 1 -dependently non-canonical Wnt/b-catenin pathway not only involved in cancer development but also inhibited TCF/LEF transcriptional activity. 35, 36 To examine the role of noncanonical Wnt pathway in BaP/DSS-induced CRC, we used western blotting to examine the expression level of calmodulin as biomarkers in Ca 21 -dependently pathway. As shown in Figure 4b , oral administration of PMFs significantly suppressed BaP/DSS induced calmodulin expression. This result indicated that BaP/DSS-induced colorectal carcinogenesis may be related to activate Ca 21 -dependent pathway. Phytochemical or drug-induced PCD, including apoptosis and autophagy, has been suggested as a potential strategy for the prevention and treatment of cancer. 37, 38 Our previous studies found that inducing a completely autophagy process inhibited cancer cell growth in vitro and in vivo model by natural dietary compounds. 30 To examine the effect of PMFs on the induction of autophagy status in BaP/DSS-induced colorectal tumorigenesis in ICR mice, we used western blotting to determine the expression level of LC3 and Beclin-1 as autophagic initiation biomarkers and targets of autophagic degradation by lysosome including p62 and conexin-43 (CX- Figure 4c , BaP/DSS significantly induced LC3 I to convert to LC3 II and Beclin-1 expression, but blocked degradation of p62 and CX-43 which contributed to defective autophagy. We also used the IHC with Beclin-1 antibody to confirm the phenomenon of autophagy. The formation of DAB puncta (brown) of Beclin-1 was only increased in the BaP/DSS-treatment group (Supporting Information, Fig. S7 ). Park et al. and Galluzzi et al. found that partial autophagic defects support malignant cell transformation. 39, 40 We used the fluorescent multiplex IHC with LC3B (green) and LAMP-1 (red) antibodies to confirm the phenomenon of autophagic defect. The formation of co-localization puncta (yellow) of LC3B and LAMP1 were inhibited in the BaP/ DSS-treatment group by suppressed autophagosomes and lysosomes that fused to form autolysosomes (Fig. 4d) . This was based on the fact that the pretreatment of mice with PMFs alleviated the BaP/DSS-induced autophagic defect.
43). As shown in
PMFs altered the composition of gut microbiota similar to control group and increased butylate-producing probiotics Gut microbiota composition is associated with a wide range of chronic human diseases as well as gastroenterologic diseases. 41, 42 In this study, we found that BaP/DSS raised an abundance of Sphingobacteriia and Gammaproteobacteria. This was decreased in mice treated with PMFs ( Fig. 5a and Supporting Information, Fig. S8A ). Moreover, the CRCrelated class Bacilli was lower in mice fed with 1.0% PMFs (1.0%) than the BaP/DSS Group (4.6%). In taxonomic order, the abundance of Erysipelortrichales and Lactobacillales was raised in DSS-induced colitis mice and in cancerous colonic tissue, respectively. 43, 44 Similar results were found in this study, but this composition of microbiota was downregulated in the PMFs pre-treatment group (Fig. 5b and Supporting  Information, Fig. S8b) . A recent study by Kim et al. demonstrated that polyphenolic inhibited colorectal inflammation and colitis increases Ruminococcaceae which includes several butyrate-producing bacteria. 45 As shown in Figure 5c and Supporting Information, Figure S8c , the levels of Ruminococcaceae and Ruminococcus were increased in the 1.0% PMFs pretreatment group to 9.8% and 9.4%, compared with the BaP/DSS group which increased to 5.3% and 2.7%. Taxonomic bins at the genus level showed that the proportion of Parabacteroides significantly increased in BaP/DSS mice while oral administration of PMFs weakened this increase ( Fig. 5d and Supporting Information, Fig. S8d) . Additionally, consumption of PMFs also altered the composition of gut microbiota and made it similar to that in the control group by increasing the butyrate-producing probiotics, such as Blautia spp., and decreasing CRC-related bacteria, such as Lactobacillus ruminis, that is involved in inducing colon inflammation through activation of toll-like receptor 5 (Fig. 5e ).
Discussion
In this study, the comprehensive tumorigenesis mechanisms induced by BaP/DSS were investigated, and we also explored how PMFs prevent BaP/DSS-induced tumor formation. At the tumor initiation stage, mice pretreated with PMFs can benefit from their protective effect on BPDE-DNA adduct generation through modulating XMEs expressed for decreasing reactive metabolites, such as BaP-quinones, and increasing detoxification metabolites in faeces. 29 The feces sample for analyzed BaP metabolites were collected during mice who were treated with BaP for 6 days, and those results explained the effects of PMFs on BaP metabolism. The expression level of XMEs was examined at the end of the treatment for 8 weeks. We will be determining the XMEs during BaP oral administration in a future study to present direct evidence for PMFs' effect on BaP metabolism via modulation XMEs.
To explain the effect of PMFs on the promotion/progression stage induced by BaP/DSS, 111 CRC-related gene expressions were determined by RNA-sequencing. As expected, BaP/ DSS significantly activated inflammatory responses, proliferation and metastasis biomarkers and reduced cell cycle regulators and antioxidation proteins. Our findings demonstrate the beneficial effects of PMFs on preventing carcinogenesis in this model by the improvement in aberrant gene expression. We also found that PCDH17, a novel TSG and involved regulation autophagy, 30 notably downregulated during BaP/DSS treatment and may participate in the defective autophagy that serves cell malignant transformation as reported by Park et al. 39 However, treatment with PMFs acts as an autophagy regulation role by ameliorating BaP/DSS-induced autophagic defects through promoted autophagosomes that fuse with lysosomes and lead to the inhibition of cancer growth. Interestingly, we discovered that BaP/DSS did not induce the expression and accumulation of b-catenin which is highly expressed in most CRC models. 25 Similar to the results observed in this study, Zuo et al. showed a downregulated Wnt/b-catenin pathway in BaP-treated mice. 46 Inhibiting the b-catenin signaling pathway may contribute to BaP induced promotion of DNA mutation. 47 Several studies suggested that the composition of gut microbiota has a close relationship with human diseases, including CRC. 42 This study is the first work to assess the effect of BaP/DSS-induced tumorigenesis on microbiota by examining the preventive effect of PMFs with oral administration. In this study, we found that BaP/DSS treatment group were significantly increased PAHs or carbon compounds degradation bacteria, such as Sphingobacteria and Gammaproteobacteria. 48 Those bacteria may be promoting BaP convert to reactive metabolites. Additionally, PAHs metabolites have been recognized to undergo enterohepatic circulation by reacted with gut microbiota contribute to intestine re-exposed reactive metabolites and increase DNA damage level. 49 The differential alterations of these gut microbiota in this study may directly lead to increasing butyrate-producing probiotics, such as Ruminococcaceae and Oscillospira, and decreasing CRC-related bacteria including Porphyromonadaceae and Lactobacillus ruminis. 50 Additionally, PMFs prevented BaP/DSS from changing the microbiota composition in that group and kept it similar to that in the healthy control group.
In conclusion, this study contributes new knowledge regarding the widespread mechanisms in BaP/DSS promoted colonic tumor formation. In addition to providing evidence towards the understanding of PMFs preventing colorectal tumorigenesis induced by BaP/DSS, this study supports PMFs as a powerful chemopreventive agent linked to modulating PAHs metabolism, regulating CRC-related gene expression and improving complete autophagy and gut microbiota homeostasis ( Supporting Information, Fig. S9 ).
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